Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideki Mitsui

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
International Journal of Hematology|March 11, 2020
Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-lineMasatoshi Sakurai, Shinichiro Okamoto, Itaru Matsumura, et al.
Leukemia & Lymphoma|May 6, 2020
Pretreatment serum soluble interleukin-2 receptor level predicts survival in patients with newly diagnosed follicular lymphomaKenji Nozaki, Hiroyuki Sugahara, Shuji Ueda, et al.
International Journal of Hematology|September 21, 2017
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 studyNaoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
International Journal of Hematology|March 11, 2020
Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-lineMasatoshi Sakurai, Shinichiro Okamoto, Itaru Matsumura, et al.
Leukemia & Lymphoma|May 6, 2020
Pretreatment serum soluble interleukin-2 receptor level predicts survival in patients with newly diagnosed follicular lymphomaKenji Nozaki, Hiroyuki Sugahara, Shuji Ueda, et al.
International Journal of Hematology|September 21, 2017
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 studyNaoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, et al.
Pageof 2